Volitionrx Ltd (VNRX) - Net Assets
Based on the latest financial reports, Volitionrx Ltd (VNRX) has net assets worth $-35.59 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.90 Million) and total liabilities ($42.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read VNRX total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-35.59 Million |
| % of Total Assets | -515.75% |
| Annual Growth Rate | N/A |
| 5-Year Change | -300.84% |
| 10-Year Change | -268.09% |
| Growth Volatility | 450.11 |
Volitionrx Ltd - Net Assets Trend (2004–2025)
This chart illustrates how Volitionrx Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Volitionrx Ltd assets under control for the complete picture of this company's asset base.
Annual Net Assets for Volitionrx Ltd (2004–2025)
The table below shows the annual net assets of Volitionrx Ltd from 2004 to 2025. For live valuation and market cap data, see Volitionrx Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-35.59 Million | -36.33% |
| 2024-12-31 | $-26.11 Million | -199.67% |
| 2023-12-31 | $-8.71 Million | -178.62% |
| 2022-12-31 | $-3.13 Million | -117.64% |
| 2021-12-31 | $17.72 Million | +8.77% |
| 2020-12-31 | $16.29 Million | +14.76% |
| 2019-12-31 | $14.20 Million | +16.95% |
| 2018-12-31 | $12.14 Million | +21.92% |
| 2017-12-31 | $9.96 Million | -52.97% |
| 2016-12-31 | $21.18 Million | +250.33% |
| 2015-12-31 | $6.04 Million | +1541.68% |
| 2014-12-31 | $368.18K | -45.91% |
| 2013-12-31 | $680.67K | -18.36% |
| 2012-12-31 | $833.79K | -23.43% |
| 2011-12-31 | $1.09 Million | +1052.82% |
| 2010-12-31 | $-114.29K | -6.27% |
| 2009-12-31 | $-107.54K | -12.11% |
| 2008-12-31 | $-95.92K | -22.48% |
| 2007-12-31 | $-78.32K | -39.30% |
| 2006-12-31 | $-56.23K | +22.91% |
| 2005-12-31 | $-72.94K | -13.91% |
| 2004-12-31 | $-64.03K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Volitionrx Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25280908600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $125.78K | % |
| Other Comprehensive Income | $-295.07K | % |
| Other Components | $218.82 Million | % |
| Total Equity | $-34.25 Million | 100.00% |
Volitionrx Ltd Competitors by Market Cap
The table below lists competitors of Volitionrx Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LL Lucky Games publ AB
ST:LADYLU
|
$18.20 Million |
|
LiqTech International Inc
NASDAQ:LIQT
|
$18.20 Million |
|
TEAM PLC
F:1WQ
|
$18.21 Million |
|
Epsium Enterprise Limited Ordinary Shares
NASDAQ:EPSM
|
$18.23 Million |
|
Nexen Tire Prf 1
KO:002355
|
$18.19 Million |
|
Lammhults Design Group AB (publ)
ST:LAMM-B
|
$18.19 Million |
|
Dev Information Technology Limited
NSE:DEVIT
|
$18.19 Million |
|
Eureka Design Public Company Limited
BK:UREKA
|
$18.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Volitionrx Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -24,907,620 to -34,246,393, a change of -9,338,773.
- Net loss of 23,357,027 reduced equity.
- New share issuances of 11,170,410 increased equity.
- Other comprehensive income decreased equity by 680,702.
- Other factors increased equity by 3,528,546.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-23.36 Million | -68.2% |
| Share Issuances | $11.17 Million | +32.62% |
| Other Comprehensive Income | $-680.70K | -1.99% |
| Other Changes | $3.53 Million | +10.3% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Volitionrx Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $-0.05 | $2.70 | x |
| 2005-12-31 | $-1.11 | $2.70 | x |
| 2006-12-31 | $-0.51 | $2.70 | x |
| 2007-12-31 | $-0.69 | $2.70 | x |
| 2008-12-31 | $-0.84 | $2.70 | x |
| 2009-12-31 | $-0.94 | $2.70 | x |
| 2010-12-31 | $-1.00 | $2.70 | x |
| 2011-12-31 | $3.78 | $2.70 | x |
| 2012-12-31 | $1.78 | $2.70 | x |
| 2013-12-31 | $1.26 | $2.70 | x |
| 2014-12-31 | $0.55 | $2.70 | x |
| 2015-12-31 | $0.34 | $2.70 | x |
| 2016-12-31 | $0.92 | $2.70 | x |
| 2017-12-31 | $0.38 | $2.70 | x |
| 2018-12-31 | $0.39 | $2.70 | x |
| 2019-12-31 | $0.36 | $2.70 | x |
| 2020-12-31 | $7.22 | $2.70 | x |
| 2021-12-31 | $6.82 | $2.70 | x |
| 2022-12-31 | $-0.93 | $2.70 | x |
| 2023-12-31 | $-2.19 | $2.70 | x |
| 2024-12-31 | $-5.76 | $2.70 | x |
| 2025-12-31 | $-6.41 | $2.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Volitionrx Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1352.16%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-200.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.78K |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.89K |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-31.36K |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.46K |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.21K |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.06K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $481.70 |
| 2011 | -239.54% | 0.00% | 0.00x | 2.06x | $-2.72 Million |
| 2012 | -489.69% | -7428.05% | 0.02x | 2.66x | $-4.17 Million |
| 2013 | -545.09% | 0.00% | 0.00x | 3.04x | $-3.78 Million |
| 2014 | -2230.85% | -55553.12% | 0.00x | 9.32x | $-8.25 Million |
| 2015 | -157.67% | 0.00% | 0.00x | 1.28x | $-10.13 Million |
| 2016 | -56.22% | 0.00% | 0.00x | 1.17x | $-14.02 Million |
| 2017 | -148.32% | 0.00% | 0.00x | 1.47x | $-15.76 Million |
| 2018 | -148.34% | 0.00% | 0.00x | 1.44x | $-19.22 Million |
| 2019 | -113.39% | -94168.55% | 0.00x | 1.50x | $-17.52 Million |
| 2020 | -124.55% | -151508.34% | 0.00x | 1.60x | $-21.99 Million |
| 2021 | -149.43% | -29782.49% | 0.00x | 1.53x | $-28.61 Million |
| 2022 | 0.00% | -9879.11% | 0.02x | 0.00x | $-30.01 Million |
| 2023 | 0.00% | -4555.53% | 0.03x | 0.00x | $-34.54 Million |
| 2024 | 0.00% | -2186.27% | 0.13x | 0.00x | $-24.48 Million |
| 2025 | 0.00% | -1352.16% | 0.25x | 0.00x | $-19.93 Million |
Industry Comparison
This section compares Volitionrx Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $757,800,566
- Average return on equity (ROE) among peers: -54.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Volitionrx Ltd (VNRX) | $-35.59 Million | 0.00% | N/A | $18.20 Million |
| Abbott Laboratories (ABT) | $7.43 Billion | 32.93% | 0.95x | $152.62 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $18.77 Million |
| Aethlon Medical Inc (AEMD) | $-7.09 Million | 0.00% | 0.00x | $2.76 Million |
| Acutus Medical Inc (AFIB) | $75.02 Million | -52.81% | 0.78x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $6.89 Million | 30.07% | 0.49x | $12.47 Million |
| Allurion Technologies, Inc. (ALUR) | $19.83K | -26.07% | 15.64x | $9.70 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $8.10 Million | -140.88% | 0.21x | $3.99 Million |
| Artivion Inc (AORT) | $30.20 Million | 15.56% | 0.78x | $1.11 Billion |
| Apyx Medical Inc (APYX) | $2.22 Million | 4.46% | 0.72x | $153.68 Million |
About Volitionrx Ltd
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleos… Read more